



Tetraphase Pharmaceuticals
Investor Relations Department
480 Arsenal Street, Suite 110
Watertown, MA 02472
United States

Visit IR website [↗](#)
Sign-up for Email alerts [↗](#)

NASDAQ: TTPH

| | |
|---------------|--|
| Last Trade: | 7.89 |
| Trade Time: | 4:00 PM ET Jun 27, 2017 |
| Change: | 0.34 ▲ (+4.503%) |
| Day Range | 7.52 - 7.97 |
| 52-Week Range | 3.11 - 9.93 |
| Volume | 882,607 |


Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Since the company's inception, Tetraphase has developed a robust antibiotics platform based on the tetracycline core chemical structure, which offers the potential to dramatically improve the treatment of serious bacterial infections. Tetraphase has utilized this fully-synthetic chemistry technology to create a pipeline of novel tetracycline antibiotics, particularly those with activity against the toughest multidrug-resistant Gram-negative bacteria.

... [\(more\)](#)

Stock Information



Press Releases [\[View all \]](#)

- Jun 5, 2017**
[Tetraphase Pharmaceuticals Announces Positive Phase 1 Single-Ascending Dose Data for Antibiotic Pipeline Candidates](#)
- May 30, 2017**
[Tetraphase Pharmaceuticals to Present at Jefferies 2017 Global Healthcare Conference](#)
- May 22, 2017**
[Tetraphase Pharmaceuticals to Present Antibiotics Pipeline Data at ASM Microbe 2017](#)
- May 4, 2017**
[Tetraphase Pharmaceuticals Reports First Quarter 2017 Financial Results and Reviews Recent Highlights](#)
- Apr 21, 2017**
[Tetraphase Pharmaceuticals to Present Data at 27th European Congress of Clinical Microbiology and Infectious Diseases \(ECCMID\)](#)

Financials & Filings [\[View all \]](#)

- Mar 13, 2017**
[Annual Report \(10-K\)](#)
- Apr 21, 2017**
[Proxy Statement \(DEF 14A\)](#)
- May 8, 2017**
[Quarterly Report \(10-Q\)](#)
- Nov 3, 2016**
[Quarterly Report \(10-Q\)](#)
- Aug 4, 2016**
[Quarterly Report \(10-Q\)](#)